These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36551591)

  • 1. Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients.
    Yue X; He D; Zheng G; Yang Y; Han X; Li Y; Zhao Y; Wu W; Chen Q; Zhang E; Cai Z; He J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
    Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.
    He J; Yue X; He D; Zhao Y; Yang Y; Zheng G; Zhang E; Han X; Wu W; Yang L; Chen J; Cai Z
    Front Oncol; 2021; 11():668099. PubMed ID: 34307138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of semi-quantitative parameters of
    Wan B; Zhang S; Wang P; Deng P; Dai W
    Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the Prognostic Value and Risk Factors of Early Relapse for Newly Diagnosed Multiple Myeloma Patients in the Era of Novel Agents].
    Li QH; Liu Y; Wang J; Wang JJ; Dong F; Yang P; Wan W; Ke XY; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):148-153. PubMed ID: 36765492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
    Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
    Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
    Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
    Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
    Pour L; Sevcikova S; Greslikova H; Kupska R; Majkova P; Zahradova L; Sandecka V; Adam Z; Krejci M; Kuglik P; Hajek R
    Haematologica; 2014 Feb; 99(2):360-4. PubMed ID: 24038024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of multiple myeloma patients with isolated extramedullary relapse.
    Qu XY; Chen LJ; Tian T; Duan LM; Lu RN; Lu H; Wu HX; Li JY
    J Biomed Res; 2018 Jul; 32(4):264-269. PubMed ID: 28963446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
    Usmani SZ; Heuck C; Mitchell A; Szymonifka J; Nair B; Hoering A; Alsayed Y; Waheed S; Haider S; Restrepo A; Van Rhee F; Crowley J; Barlogie B
    Haematologica; 2012 Nov; 97(11):1761-7. PubMed ID: 22689675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case-control study of multiple myeloma patients with central nervous system involvement].
    Li L; Feng ZY; Guo P; He HY; Lu J; Liu J; Qiang WT; Jiang H; Du J; Fu WJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1016-1020. PubMed ID: 36709107
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
    Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
    Gao XY; Ma YP; Chao Y; Fan L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):547-552. PubMed ID: 33812429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.
    Song Y; Du J; Jin X; Li H; Jia C; Liu Y; Li K; Zhou D; Zhuang J
    Eur J Haematol; 2024 Dec; 113(6):824-832. PubMed ID: 39191670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??
    Kaloyannidis P; Abdulla F; Mutahar E; Al Hashim H; Al Harbi S; Estanislao A; Al Hashmi H
    J Blood Med; 2022; 13():619-630. PubMed ID: 36317167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
    Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
    [No Abstract]   [Full Text] [Related]  

  • 19. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
    Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma.
    Batsukh K; Lee SE; Min GJ; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Min CK
    Immune Netw; 2017 Aug; 17(4):250-260. PubMed ID: 28860954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.